Short answer
RxSight, Inc. (RXST) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results announcement for the three months ended September 30, 2026.
RxSight, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 results announcement for the three months ended September 30, 2026
- Detailed financial results and operating metrics available in Exhibit 99.1
- Investor focus: quarterly performance, liquidity, and outlook in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $24.6M, down 19% YoY, signaling intensified competitive pressure and weaker near-term demand
- LAL volume 23,128 units, while Alcon collaboration revenue was only $40K during the quarter
- Gross margin fell to 73.6% from 79.9%, pressured by inventory reserves and higher LAL and LDD costs
- GAAP net loss widened to $16.2M, or $0.39 per share, from $9.8M, or $0.24 per share
- Liquidity totaled $254.7M, including $60M from Alcon, supporting commercial expansion and restructuring execution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RxSight, Inc. 8-K filings
Get the next RXST 8-K as it lands
Follow RXST for push alerts, or ask the research agent what this filing means.